Abstract：Objective To observe the therapeutic effect of Bifidobacterium tetravaccine Tablets(live), Clostridium butyricum powder, Saccharomyces boulardii sachets combined with Mesalazine SR granules on mild or moderate ulcerative colitis.Methods A total of 160 patients who had been treated between January 2014 and December 2016 were randomly divided into the trail group and three control groups(40 patients in each group). Each of the control groups took two types of probiotic agents (not the same type between the three control groups) and Mesalazine SR granules, while the trail group took the three types of probiotic agents and Mesalazine SR granules. The therapy lasted 4 weeks. Mayo activity index scores, fecal calprotectin values, colonoscopy scores, gastrointestinal quality of life indexes and clinical effect were compared between the trail group and control group.Results After treatment, the Mayo activity index score in the trail group was reduced to 1.43±; 0.86, fecal calprotectin value to 135.33±; 95.53, colonoscopy score to 2.17±; 1.21, while the gastrointestinal quality of life index was elevated to 114.33±; 13.51. There was statistically significant difference (P<; 0.05) between the trail group and each control group in the above indicators. The changes were also statistically significant after treatment in each group (P<; 0.05), but there was not statistically significant difference between the control groups. There was some correlation between the Mayo score and fecal calprotectin levels.Conclusions Bifidobacterium tetravaccine Tablets(live), Clostridium butyricum powder, Saccharomyces boulardii sachets combined with Mesalazine SR granules are effective and safe for mild or moderate ulcerative colitis.
Frank D N,Robertson C E,Hamm C M, et al . Disease phenotype and genotype are associated with shifts in intestinal-associated microbiota in inflammatory bowel diseases [J]. Int J Colorectal Dis, 2011, 17(1): 179- 184.
[2]
Ricanek P,Lothe S M,Frye S A, et al . Gut bacterial profile in patients newly diagnosed with treatment-naïve Crohn’s disease [J]. Clin Exp Gastroenrerol, 2012, 5(1): 173-186.
[3]
Kaakoush N O, Day A S, Huinao K D, et al . Microbial dysbiosis in pediatric patients with Crohn’s disease[J]. Clin Microbiol, 2012, 50(10): 3258-3266.
Yamamoto T,Shiraki M,Bamba T, et al . Fecal calprotectin and lactoferrin as predictors of relapse in patients with quiescent ulcerative colitis during maintenance therapy [J]. Int J Colorectal Dis, 2014, 29(4):485- 491.
Kump P K,Gröchenig H P,Lackner S, et al . Alteration of intestinal dysbiosis by fecal microbiota transplantation does not induce remission in patients with chronic active ulcerative colitis[J]. Inflamm Bowel Dis, 2013, 19(10): 2155-2165.
[9]
Quintana J M,Cabriada J,López de Tejada I, et al . Translation and validation of the gastrointestinal quality of Life Index (GIQLI) [J]. Rev Esp Enferm Dig, 2001, 93(11): 693-706.
[10]
Van Nood E,Speelman P,Nieuwdorp M, et al . Fecal microbiota transplantation: facts and controversies [J]. Curr Opin Gastroenterol, 2014, 30(1): 34-39.
[11]
Purchiaroni F, Tortora A,Gabrielli M, et al . The role of intestinal microbiota and the immune system [J]. Eur Rev Med Pharmacol Sci, 2013, 17(3): 323- 333.
Boon G J, Day A S, Mulder C J, et al . Are faecal markers good indicators of mucosal healing in inflammatory bowel disease?[J]. World J Gastroenterology, 2015,21(40):11469-11480.
[14]
Schoepfer A M, Beglinger C, Straumann A, et al . Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes [J]. Inflamm Bowel Dis, 2013, 19(2): 332-341.
2017, Vol. 28 
